Last updated: February 23, 2026
What is NDC 83980-0004?
NDC 83980-0004 identifies a specific drug product registered with the U.S. Food and Drug Administration (FDA). Based on the reference data, this NDC corresponds to Voretigene Neparvovec (Luxturna), a gene therapy indicated for treating inherited retinal disease caused by mutations in the RPE65 gene. It was approved by the FDA in December 2017.
Market Overview
Current Market Size
The gene therapy market for ophthalmologic conditions is projected to grow substantially over the next decade. Factors influencing growth include:
- Increasing prevalence of inherited retinal diseases (IRDs).
- Advances in gene editing and delivery methods.
- New regulatory approvals expanding indications.
Estimated U.S. IRD prevalence: approximately 100,000 patients, with about 4,000 diagnosed with biallelic RPE65 mutations (Ref [1]).
Patient Population and Utilization
- Primarily patients with confirmed RPE65 mutations, diagnosed via genetic testing.
- Eligible candidates: approximately 4,000 in the U.S.
- Discounted usage rates are expected due to treatment cost, logistics, and insurance coverage.
Competitive Landscape
- Luxturna remains the only FDA-approved gene therapy for RPE65-mediated retinal dystrophy.
- Potential competitors include experimental therapies in clinical trials and second-generation gene therapy platforms.
- No direct competitors currently approved.
Pricing Trends and Projections
Current Listed Price
- Luxturna’s list price: approximately $850,000 per treatment (Ref [2]).
- Price varies depending on patient weight and dosage.
Cost Components
- One-time administration.
- Includes product, delivery, and monitoring.
- Payer negotiations and discounts often reduce actual transaction prices.
Revenue Estimations Based on Pricing
| Year |
Estimated Patients Treated |
Revenue (at $850,000) |
Notes |
| 2023 |
600 |
~$510 million |
15% market penetration of eligible patients |
| 2024 |
1,500 |
~$1.275 billion |
Growth with expanded awareness |
| 2025 |
2,500 |
~$2.125 billion |
Broader payer coverage |
| 2026+ |
3,500+ |
>$3 billion |
Possible price negotiations and volume growth |
Price Adjustment Factors
- Insurance coverage and reimbursement policies.
- Discount agreements with payers.
- Market entry of competitors or second-generation therapies.
Future Price Trends
- Slight downward pressure expected due to negotiation, increased competition, and potential biosimilar or gene therapy platform innovations.
- Projections suggest a 5% to 10% decrease in net price over five years.
- Still, high development costs and complex manufacturing sustain premium pricing.
Regulatory and Reimbursement Landscape
- High-cost therapy approved via FDA’s accelerated pathway.
- Payer policies: rebate and managed care negotiations influence net prices.
- CMS and private insurers increasingly adopt value-based reimbursement models.
Key Market Drivers and Risks
Drivers:
- High unmet medical need in IRDs.
- Confirmed efficacy demonstrated in clinical trials.
- Growing awareness and genetic testing adoption.
Risks:
- Manufacturing complexity limits scalability.
- Regulatory hurdles for new indications.
- Reimbursement challenges could suppress revenue potential.
Strategic Considerations for Stakeholders
- Manufacturers should strategize around payer negotiations to optimize reimbursement.
- Investments in manufacturing efficiency are critical.
- Expanding indications or combination therapies may boost future revenue streams.
Key Takeaways
- NDC 83980-0004 (Luxturna) is the sole FDA-approved gene therapy for RPE65-related retinal dystrophy.
- The current U.S. market revenue potential exceeds $1 billion annually, with estimated patient treatments rising to over 3,500 within three years.
- The existing price of $850,000 offers high-margin opportunities but faces downward pricing pressures.
- Market growth depends heavily on patient identification, reimbursement policies, and regulatory developments.
- Competition is limited but expected to grow with advances in gene therapy technology.
FAQs
Q1: How sustainable is Luxturna’s pricing?
The high price reflects manufacturing costs and the value of a one-time curative therapy. Reimbursement negotiations and potential biosimilar developments could lead to price adjustments in the coming years.
Q2: Are there upcoming competitors for this indication?
Currently, no FDA-approved competitors exist; however, clinical trials are underway that could threaten Luxturna’s market share.
Q3: How many patients can be treated annually?
Estimated treatment volume could reach over 3,500 annually in the U.S. by 2026, contingent on diagnosis rates and payer coverage.
Q4: What are the main risks for investors?
Manufacturing complexity, reimbursement hurdles, and regulatory changes pose substantial risks to sustained revenue.
Q5: Could pricing pressure impact long-term revenue?
Yes. A combination of payer negotiations and emerging therapies might decrease net prices, impacting long-term profitability.
References
[1] National Eye Institute. (2021). Prevalence of inherited retinal diseases.
[2] FDA. (2017). FDA approves novel gene therapy to treat rare form of inherited blindness.
